Mubadala Exits Arcadia Consumer Healthcare as Bansk Group Assumes Full Control in Continuation Vehicle

Mubadala Capital has sold its minority stake in Arcadia Consumer Healthcare to funds managed by Bansk Group, marking the end of a four-year partnership that tripled the platform’s revenue and sharpened its profitability. The transaction, structured as a continuation fund deal backed by Coller Capital and Ares Management, positions Bansk to pursue further growth in the resilient U.S. consumer health sector.[2][1]

Most “AI for Diligence” tools are lying to you. The truth is, they are just ChatGPT wrappers. Experience what real AI for Diligence looks like, built like Claude Code, but for M&A/ PE Diligence:

💼 When Claude Code Marries Due Diligence!

Deal Structure and Financial Performance

Financial terms remain undisclosed, but the exit highlights **private equity continuation fund strategies** in healthcare platforms, allowing sponsors like Bansk to extend holding periods amid favorable market dynamics. During Mubadala’s involvement since 2022, Arcadia expanded its portfolio of over-the-counter brands—including Nizoral, Colace, Senokot, CloSYS, Betadine, and Kaopectate—through bolt-on acquisitions like Avrio and CloSYS. Revenue tripled, with material profitability gains driven by operational efficiencies and resilient consumer demand for wellness products.[2]

Philip Yifei Bao, director of private equity at Mubadala, noted the partnership accelerated Arcadia’s transformation into North America’s leading consumer health platform. Bansk credited Mubadala’s patient capital approach for enabling key integrations and scaling.[2]

Strategic Context in Consumer Healthcare M&A

The deal underscores sustained **private equity interest in consumer healthcare exits**, where platforms benefit from defensive growth profiles amid economic volatility. Bain & Company reports that consumer health M&A volumes rose 15% in 2025, fueled by aging demographics and post-pandemic wellness trends, with median EV/EBITDA multiples holding at 12-14x for platforms like Arcadia.[1] Similar transactions include Thoma Bravo’s roll-ups in adjacent wellness segments and KKR’s investments in European OTC leaders.

Bansk’s continuation vehicle, supported by Coller and Ares, extends the fund life for Arcadia, providing fresh capital for add-ons without returning capital to limited partners prematurely—a tactic increasingly common in mid-market PE, per McKinsey’s 2025 Private Equity Report, where 25% of exits involved continuation funds.[1]

Broader Implications for PE Healthcare Strategies

This exit aligns with Mubadala’s track record in healthcare PE, including prior realizations in medtech and pharma services. For Bansk, full control enables aggressive pursuit of **consumer health platform consolidation**, targeting synergies in distribution and R&D. Goldman Sachs research flags U.S. OTC markets growing at 7% CAGR through 2030, driven by self-care shifts, positioning assets like Arcadia for premium valuations in future liquidity events.

Regulatory tailwinds, including FDA streamlining for OTC approvals, further bolster the sector, though antitrust scrutiny on roll-ups persists, as seen in FTC reviews of similar deals. Kirkland & Ellis advises that continuation funds mitigate GP-LP tensions in extended hold periods, a trend accelerating **healthcare private equity exit strategies** into 2026.[1]

• Arcadia’s model mirrors successful PE-backed platforms like Church & Dwight’s consumer health arm, emphasizing brand aggregation.
• Bansk’s backers—Coller for secondaries expertise and Ares for credit—signal confidence in 15-20% IRR potential.
• Market parallel: Bridgepoint and Triton’s interest in UK hospital group Spire reflects transatlantic PE appetite for healthcare services.[1]